A person's metabolism is as unique as their fingerprint, and so is their risk of developing certain diseases. A better understanding of the genetic influences on metabolism could open up new therapeutic options. Researchers at the Berlin Institute of Health at Charité (BIH) and Queen Mary University…
The Berlin Institute of Health at Charité (BIH) is coordinating the central European research project "EU-CiP" (European Cancer Information Portal). This project is funded with 12 million euros over four years by the European Union's Horizon Europe program. For the first time, it establishes a…
The Berlin Institute of Health at Charité (BIH) and ProBioGen today announced a major collaboration to manufacture materials for gene and cell therapies. The partnership was unveiled at the groundbreaking ceremony for the Berlin Center for Gene and Cell Therapies (BC GCT), which features a 4,600 m²…
An international research team bringing together Prof. Kirsten Kübler from the Berlin Institute of Health at Charité (BIH), and colleagues from Broad Institute of MIT and Harvard, Mass General Brigham and Dana-Farber Cancer Institute has identified a previously unknown mechanism by which the breast…
An interdisciplinary team of scientists from the Berlin Institute of Health at Charité (BIH), the Max Delbrück Center, the German Cancer Research Center (DKFZ), the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM) and Queen Mary University of London, UK, has…
Hospitals generate vast amounts of data every day, which have the potential to significantly improve patient care. dotbase medical GmbH, a spin-off of the Berlin Institute of Health at Charité (BIH) and Charité – Universitätsmedizin Berlin, has developed a platform that brings together data in a…
Myasthenia gravis is a rare neurological autoimmune disease characterized by fluctuating muscle weakness that worsens with activity. About 17,000 people in Germany suffer from the disease. Many struggle to access appropriate care, especially if they need complex immunotherapies. The start-up…
With the support of SPARK-BIH and the BIH Biomedical Innovation Academy (BIA), the first cohorts in the project and personal funding programs of the National Strategy for Gene- and Cell-Based Therapies (GCT) have been selected. Within the project funding according to the SPARK method, 17 projects…
Aiming to bridge the gap between cutting-edge biomedical research and real-world clinical application, the Berlin Institute of Health at Charité (BIH) entered into an agreement with BioLabs, an internationally known innovation laboratory platform with a network of shared lab and office workspaces,…
